Adrenomyeloneuropathy Questions & Answers - David Isserman

David Isserman ( biotechguy )

About me

My name is David Isserman and I am one of the co-founders of RareShare. I also work full-time for Nutra Pharma Corporation, a biotechnology company that is researching a treatment for Adrenomyeloneuropathy (AMN) as well as treatments for other neurological and autoimmune disorders.

If you have any questions or feedback regarding RareShare, please feel free to contact me directly at david@rareshare.org.

Website
View my website

You must be a member of this community to ask a question.

chrisphillips71 asked "

Dave,
Can you please update us on the status of RPI-78M? For example, are any studies currently being performed? Is there an estimate on when RPI-78M will be submitted to the FDA for approval?

Also, a brief synopsis on the the expected benefits of RPI-78M would be helpful. For example, does RPI-78M reverse the effects of adrenomyelneuropathy or does it just halt the course of the disease?

Your thoughts are greatly appreciated.
Thank you.

"

Thank you for your question. As many of you know, RPI-78M, was under study for the treatment of AMN. Nutra Pharma completed this study in July 2008 and released initial positive safety data in August 2008. Currently, the data from this study is under review. Until the final analysis has been completed at the MHRA, Nutra Pharma cannot release any additional details. The MHRA is a British regulatory agency, similar to the FDA in the United States.

Best regards,
David